Total laparoscopic right hemicolectomy with transvaginal specimen extraction for the treatment of right-sided colon cancer: a local experience

Abstract

Abstract Background To investigate the safety, feasibility, and oncological outcomes of total laparoscopic right hemicolectomy with transvaginal specimen extraction in the treatment of right-sided colon cancer. Methods We retrospectively reviewed patients with right-sided colon cancer who received total laparoscopic right hemicolectomy in our hospital between January 2017 and January 2020. The patients who underwent abdominal incision were included in the control group and the patients who underwent vaginal incision group were included in the study group. The perioperative characteristics and outcomes were compared between these two groups. Results 25 patients were included in the study group and 55 patients were included in the control group. In terms of baseline data, including age, preoperative body mass index, American Society of Anesthesiologists classification, tumor transverse diameter, tumor location, pathologic differentiation, preoperative clinical staging, there were no significant differences between the two groups (P > 0.05). There were no significant differences in terms of operative duration, intraoperative blood loss, length of resected colon, number of detected lymph nodes, postoperative complications, and postoperative pathological stages between the two groups (P > 0.05). There were statistically significant differences in postoperative pain intensity, time to passage of flatus, and length of postoperative hospital stay between the two groups (P < 0.05). The sexual function index survey showed a statistically significant difference at 3 months (P < 0.05), but not 6 months (P > 0.05), after the surgery between the two groups. The one-year tumor-free survival rate was 100% in both groups. Conclusions Total laparoscopic right hemicolectomy with transvaginal specimen extraction is a safe and feasible method, with satisfactory oncological outcomes, to treat patients with right-sided colon cancer.